Data from Colorectal Cancer Screening with Blood-Based Biomarkers: Cost-Effectiveness of Methylated Septin 9 DNA versus Current Strategies

MLA

Scott Ramsey, et al. Data from Colorectal Cancer Screening with Blood-Based Biomarkers: Cost-Effectiveness of Methylated Septin 9 DNA versus Current Strategies. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1055-9965.c.6515856.v1.

APA

Scott Ramsey, Michael Wandell, John Allen, & Uri Ladabaum. (2023). Data from Colorectal Cancer Screening with Blood-Based Biomarkers: Cost-Effectiveness of Methylated Septin 9 DNA versus Current Strategies. https://doi.org/10.1158/1055-9965.c.6515856.v1

Chicago

Scott Ramsey, Michael Wandell, John Allen, and Uri Ladabaum. 2023. “Data from Colorectal Cancer Screening with Blood-Based Biomarkers: Cost-Effectiveness of Methylated Septin 9 DNA versus Current Strategies,” March. doi:10.1158/1055-9965.c.6515856.v1.